Teva, Mylan, Ranbaxy, Takeda sales and marketing update

The companies launched generic versions of diabetes drugs Actos pioglitazone and ACTOplus met pioglitazone/metformin in the U.S. Ranbaxy and Teva launched authorized generics of Actos, while Mylan and Teva launched authorized generics of ACTOplus met. Earlier this month, FDA approved a generic version of Actos from Mylan, which launched the product immediately. Mylan has 180 days of generic marketing exclusivity for both products. Teva and Ranbaxy declined to disclose the price, while Mylan could not be reached. Takeda markets the branded version of the products. The patents for Actos expire in 2016. ...